Sarah Gheuens - 10 Feb 2022 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role: Chief Medical Officer
Signature: /s/ William Cook, as attorney-in-fact for Sarah Gheuens
Issuer symbol: AGIO
Transactions as of: 10 Feb 2022
Net transactions value: -$23,820
Form type: 4
Filing time: 14 Feb 2022, 15:09:21 UTC
Previous filing: 07 Dec 2021
Next filing: 23 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGIO	Common stock	Options Exercise	$0	+2,162	+53%	$0.000000	6,210	10 Feb 2022	Direct	F1
transaction	AGIO	Common stock	Tax liability	$23,820	-758	-12%	$31.42	5,452	10 Feb 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGIO	Restricted stock units	Options Exercise	$0	-2,162	-33%	$0.000000	4,324	10 Feb 2022	Common stock	2,162		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2	The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments.